{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:07:28Z","timestamp":1791976048103,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Innogen Pharmaceutical Co. Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40262-025-01541-0","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T04:54:12Z","timestamp":1751259252000},"page":"1367-1377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct05694221","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xiaojie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2966-9149","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"4","key":"1541_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"issue":"3","key":"1541_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203\u201316.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1541_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1541_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"9","key":"1541_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/ijo.2012.208","volume":"37","author":"JJ Holst","year":"2013","unstructured":"Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013;37(9):1161\u20138.","journal-title":"Int J Obes (Lond)"},{"issue":"10","key":"1541_CR6","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Investig. 2014;124(10):4473\u201388.","journal-title":"J Clin Investig"},{"issue":"2","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JOE-20-0255","volume":"248","author":"Q Cui","year":"2021","unstructured":"Cui Q, Liao Y, Jiang Y, et al. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J Endocrinol. 2021;248(2):145\u201354.","journal-title":"J Endocrinol"},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fphys.2019.00930","volume":"10","author":"L Ren","year":"2019","unstructured":"Ren L, Cui Q, Liu W, et al. Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. Front Physiol. 2019;10:930.","journal-title":"Front Physiol"},{"issue":"4","key":"1541_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-025-01475-7","volume":"64","author":"YR Lou","year":"2025","unstructured":"Lou YR, Xu YL, Xiong Y, et al. Population pharmacokinetics of efsubaglutide alfa in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2025;64(4):533\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"1541_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1541_CR11","first-page":"790","volume":"12","author":"E Jimenez-Solem","year":"2010","unstructured":"Jimenez-Solem E, Rasmussen MH, Christensen M, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12(6):790\u20137.","journal-title":"Curr Opin Mol Ther"},{"issue":"4","key":"1541_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrd2909","volume":"11","author":"PM Hogarth","year":"2012","unstructured":"Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11(4):311\u201331.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1541_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012734","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Chen K, Liu R, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS\u00a0One. 2010;5(9): e12734.","journal-title":"PLoS\u00a0One"},{"key":"1541_CR14","doi-asserted-by":"crossref","unstructured":"Ma A, Zhou Y, Lou Y-R, et al. 93-LB: a randomized clinical trial of safety, pharmacokinetics, and pharmacodynamics of weekly dosing supagutide in healthy Chinese subjects. Diabetes. 2022;71(Supplement_1):93-LB","DOI":"10.2337\/db22-93-LB"},{"key":"1541_CR15","doi-asserted-by":"crossref","unstructured":"Wang Q, Zhou Y, Wang W, et al. 757-P: efficacy and safety of supaglutide monotherapy in patients with type 2 diabetes. Diabetes. 2023;72(Supplement_1):757-P","DOI":"10.2337\/db23-757-P"},{"key":"1541_CR16","doi-asserted-by":"crossref","unstructured":"Anwar D, Bao Y, Zhou Y, et al. 778-P: efficacy and safety of supaglutide as add-on to metformin in patients with type 2 diabetes. Diabetes. 2023;72(Supplement_1):778-P","DOI":"10.2337\/db23-778-P"},{"key":"1541_CR17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fphys.2017.00294","volume":"8","author":"Y Wan","year":"2017","unstructured":"Wan Y, Huang J, Zhang X, Liu W, Cui Q, Jiang D, Wang Z, Liu R, Wang Q. Novel GLP-1 analog supaglutide reduces HFD-induced obesity associated with increased Ucp-1 in white adipose tissue in mice. Front Physiol. 2017;8:294.","journal-title":"Front Physiol"},{"issue":"3","key":"1541_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"BC Mccreight Lj","year":"2016","unstructured":"Mccreight Lj BC, Pearson ER. Metformin and the gas-trointestinal tract. Diabetologia. 2016;59(3):426\u201335.","journal-title":"Diabetologia"},{"issue":"2","key":"1541_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.24953\/turkjped.2019.02.013","volume":"61","author":"M Mutlu","year":"2019","unstructured":"Mutlu M, Aslan Y, Kader \u015e, et al. Clinical signs and symptoms of toxic serum digoxin levels in neonates. Turk J Pediatr. 2019;61(2):244\u20139.","journal-title":"Turk J Pediatr"},{"issue":"2","key":"1541_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/HPC.0b013e318221e7dd","volume":"10","author":"M Ehle","year":"2011","unstructured":"Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Crit Pathw Cardiol. 2011;10(2):93\u20138.","journal-title":"Crit Pathw Cardiol"},{"key":"1541_CR21","unstructured":"Food and Drug Administration (FDA), Digoxin lable. https:\/\/www.medicines.org.uk\/emc\/medicine\/23944. Accessed 29 Mar 2025."},{"key":"1541_CR22","unstructured":"Food and Drug Administration (FDA), Metformin label. https:\/\/dailymed.nlm.nih.gov\/dailymed\/downloadpdffile.cfm?setId=1ef6c527-89f5-4830-8900-7532b0a7ef26. Accessed 29 Mar 2025."},{"issue":"1","key":"1541_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13318-011-0028-y","volume":"36","author":"C Friedrich","year":"2011","unstructured":"Friedrich C, Ring A, Brand T, et al. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2011;36(1):17\u201324.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"1541_CR24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/cpdd.849","volume":"9","author":"XM Huang","year":"2020","unstructured":"Huang XM, Wang GZ, He BB, et al. Bioequivalence and pharmacokinetic evaluation of two metformin hydrochloride tablets under fasting and fed conditions in healthy chinese volunteers. Clin Pharmacol Drug Dev. 2020;9(8):910\u20137.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1541_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1345\/aph.1Q583","volume":"46","author":"KMHNR Pinelli","year":"2012","unstructured":"Pinelli KMHNR. Drug-drug interactionswith glucagon-like peptide-i receptor agonists. Ann Pharmacother. 2012;46:710\u20137.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1541_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40262-017-0532-6","volume":"56","author":"H Hausner","year":"2017","unstructured":"Hausner H, Derving Karsb\u00f8l J, Holst AG, et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet. 2017;56(11):1391\u2013401.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1541_CR27","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.14110","volume":"22","author":"S Urva","year":"2020","unstructured":"Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1541_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.962","volume":"10","author":"EK Langeskov","year":"2022","unstructured":"Langeskov EK, Kristensen K. Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. Pharmacol Res Perspect. 2022;10(4): e00962.","journal-title":"Pharmacol Res Perspect"},{"key":"1541_CR29","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/5584_2020_496","volume":"1307","author":"DB Maselli","year":"2021","unstructured":"Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171\u201392.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"1541_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3810\/pgm.2012.11.2613","volume":"124","author":"M Bush","year":"2012","unstructured":"Bush M, Scott R, Watanalumlerd P, et al. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124(6):55\u201372.","journal-title":"Postgrad Med"},{"issue":"11","key":"1541_CR31","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1021\/acs.molpharmaceut.5b00278","volume":"12","author":"M Malm-Erjef\u00e4lt","year":"2015","unstructured":"Malm-Erjef\u00e4lt M, Ekblom M, Vouis J, et al. Effect on the Gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharm. 2015;12(11):4166\u201373.","journal-title":"Mol Pharm"},{"issue":"9","key":"1541_CR32","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1177\/0091270005278806","volume":"45","author":"PA Kothare","year":"2005","unstructured":"Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45(9):1032\u20137.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"1541_CR33","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s40262-017-0531-7","volume":"56","author":"A De La Pe\u00f1a","year":"2017","unstructured":"De La Pe\u00f1a A, Cui X, Geiser J, et al. No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide. Clin Pharmacokinet. 2017;56(11):1415\u201327.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1541_CR34","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/biomedicines9101360","volume":"9","author":"N Youssef","year":"2021","unstructured":"Youssef N, Noureldein M, Njeim R, et al. Reno-protective effect of GLP-1 receptor agonists in type1 diabetes: dual action on TRPC6 and NADPH oxidases. Biomedicines. 2021;9(10):1360.","journal-title":"Biomedicines"},{"issue":"4","key":"1541_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13300-020-00798-x","volume":"11","author":"WL Yin","year":"2020","unstructured":"Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes. Diabetes Ther. 2020;11(4):835\u201344.","journal-title":"Diabetes Ther"},{"issue":"6","key":"1541_CR36","doi-asserted-by":"publisher","DOI":"10.2174\/1573399820666230809152148","volume":"20","author":"S Seksaria","year":"2024","unstructured":"Seksaria S, Dutta BJ, Kaur M, et al. Role of GLP-1 Receptor agonist in diabetic cardio-renal disorder: recent updates of clinical and pre-clinical evidence. Curr Diabetes Rev. 2024;20(6): e090823219597.","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"1541_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.31128\/AJGP-02-20-5222","volume":"50","author":"NR Andrew Marson","year":"2021","unstructured":"Andrew Marson NR, Rawa O, Gary D. Management of patients with type 2 diabetes and cardiovascular disease in primary care. Aust J Gen Pract. 2021;50(4):238\u201345.","journal-title":"Aust J Gen Pract."},{"issue":"4","key":"1541_CR38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173(4):278\u201386.","journal-title":"Ann Intern Med"},{"key":"1541_CR39","doi-asserted-by":"publisher","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1149328.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1541_CR40","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/DMSO.S348025","volume":"15","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Chen M, Liu L, et al. Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study. Diabetes Metab Syndr Obes. 2022;15:155\u201363.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1541_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12: 645563.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01541-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:13:08Z","timestamp":1757466788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01541-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01541-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"13 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Innogen Pharmaceutical Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Qinghua Wang is the founder of Innogen Pharmaceutical Co. Ltd. Yulong Xu is an employee of Innogen Pharmaceutical Co. Ltd. The remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest:"}},{"value":"The study was approved by the relevant ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice (ICH-GCP).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data will be made available upon reasonable request, participant to the protection of research participants\u2019 privacy.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Jinjie He, Xiaojie Wu, and Yulong Xu drafted the manuscript. Jing Zhang, Xiaojie Wu, Jinjie He, Wei Liu, Junzhen Wu, and Yiming Li made important contributions to participants recruitment and safety evaluation. Jing Zhang, Xiaojie Wu, Yulong Xu, and Qinghua Wang reviewed and edited the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}